论文部分内容阅读
The p53 gene has been widely investigated and considered to be an effective tumor suppressor in cancer gene therapy [1].To realize the clinical application ofp53-based gene therapy,developing safe and efficient gene carriers is necessary.Non-viral gene carriers including 25 kDa branched polyethylenimine (PEI25K) have been demonstrated to be more promising than viral carriers.However,the inherent shortcomings of PEI25K,such as cytotoxicity,adsorption of serum proteins and acceleration of reticuloendothelial system removal,would significantly limit its application scope.